A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis (FRONTIER 4) (FRONTIER-4)
This is a research study to determine the efficacy and safety of investigational drug
MEDI3506 for the treatment of adult subjects with Chronic Obstructive Pulmonary Disease and
Study D9180C00002 is a Phase II, randomised, double-blind, placebo-controlled, parallel
group, proof of concept study to evaluate the efficacy and safety of MEDI3506 in adult
participants with moderate to severe Chronic Obstructive Pulmonary Disease and Chronic
Approximately 100 sites globally will participate in this study. Approximately 144
participants will be randomized to 2 treatment groups in a 1:1 ratio to receive MEDI3506 or
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.